4D Molecular Therapeutics (NASDAQ:FDMT) Releases Earnings Results, Misses Expectations By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) announced its quarterly earnings results on Friday. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Performance

NASDAQ:FDMT traded up $0.05 during mid-day trading on Friday, reaching $4.53. The stock had a trading volume of 1,216,752 shares, compared to its average volume of 826,217. The business has a 50 day simple moving average of $5.26 and a 200 day simple moving average of $8.71. The firm has a market capitalization of $209.41 million, a price-to-earnings ratio of -1.59 and a beta of 2.81. 4D Molecular Therapeutics has a twelve month low of $4.20 and a twelve month high of $36.25.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on FDMT. Leerink Partners dropped their price objective on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Chardan Capital dropped their price target on shares of 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, February 10th. BMO Capital Markets cut 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. Finally, Morgan Stanley decreased their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research note on Monday, January 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $32.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.